Abstract: New peptidomimetic inhibitors of retroviral proteases are in particular for human immunodeficiency virus (HIV) protease. These inhibitors include as the core structure a new diamiriodiol isostere of the dipeptide Phe-Pro having four stereogenic centers. The inhibitors have been shown to inhibit HIV-protease and can therefore be usefully employed as antivirals for post-exposure prophylaxis and as a therapy for viral infections by a retrovirus, in particular HIV. The syntheses processes of the isosteres and inhibitors are also described.
Abstract: The invention provides compounds, compositions and uses of compounds of general formula (I) or (I?), or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder.
Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.
Type:
Grant
Filed:
September 5, 2003
Date of Patent:
April 6, 2010
Assignee:
Biogen Idec MA Inc.
Inventors:
Wen-Cherng Lee, Mary Beth Carter, Lihong Sun, Paul Lyne, Claudio Chuaqui, Zhongli Zheng, Juswinder Singh, Paula Boriack-Sjodin
Abstract: The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.
Type:
Grant
Filed:
July 28, 2006
Date of Patent:
April 6, 2010
Assignee:
McNeil-PPC, Inc.
Inventors:
Christopher E. Szymczak, James T. Walter
Abstract: Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Abstract: The present invention relates to the use of one or more of the compounds of the group consisting of 4-thiouridine, isomaltitol, and uridine in the preparation of therapeutically effective compositions against acute or chronic inflammations, and/or problems in hemostasis related to platelet function, as well as a method for treatment of acute or chronic inflammations, and/or problems in hemostasis related to platelet function with the exception of the use of uridine in the treatment of inflammatory conditions caused by a bacterial infection.
Abstract: A pharmaceutical composition for the treatment and/or prevention of cerebral ischemic diseases, which comprises two components, i.e. an astrocyte function-improving agent, preferably a compound represented by the formula (I): (wherein R6 is hydroxy, etc., (1) n is 1, R11 is hydrogen and R5 is (alkyl of which one carbon atom is substituted by fluorine)-CH2— or (2) n is 0 or 1, R11 is hydrogen, etc., and R5 is alkyl, etc.) and a thrombolytic agent, preferably tissue plasminogen activator, as active ingredients. The pharmaceutical composition of the present invention exhibits a synergistic therapeutic effect compared to independent administration of an astrocyte function-improving agent and a thrombolytic agent.
Abstract: The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis.
Abstract: The invention relates to the use of a deoxynojirimycin derivative, or pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of insulin resistance, hyperpigmentation and/or inflammatory processes in the skin, a fungal disease, overweight and obesity, or a microbacterial infection.
Type:
Grant
Filed:
October 29, 2004
Date of Patent:
February 16, 2010
Assignee:
Genzyme Corporation
Inventor:
Johannes Maria Franciscus Gerardus Aerts
Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
February 9, 2010
Assignee:
AstraZeneca AB
Inventors:
Cathy Dantzman, Glen Ernst, Megan Murphy King
Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
January 5, 2010
Assignee:
Allergan, Inc.
Inventors:
Chin-Ming Chang, Gary J. Beck, Cynthia C. Pratt, Amy L. Batoosingh
Abstract: An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.
Type:
Grant
Filed:
August 28, 2006
Date of Patent:
January 5, 2010
Assignees:
Baxter International Inc., Baxter Healtcare S.A.
Abstract: In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.
Type:
Grant
Filed:
February 23, 2000
Date of Patent:
December 29, 2009
Assignee:
The Regents of the University of California
Abstract: A hearing health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C (Calcium Ascorbate), Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q10, R-alpha Lipoic Acid, L-Carnitine and mixtures thereof.
Type:
Grant
Filed:
April 1, 2008
Date of Patent:
December 22, 2009
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, Gerald M. Haase, William C. Cole
Abstract: A heart and pulmonry health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the formulation comprising dietary micronutrients and endogenous antioxidants, the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C, Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q10, R-alpha Lipoic Acid, Omega-3 fatty Acid, and L-Carnitine and mixtures thereof.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
December 8, 2009
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, Gerald M. Haase, William C. Cole
Abstract: The invention concerns the combination of a short-acting hypnotic agent and a compound of formula (I): Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The combination of this invention is useful in treating a variety of sleep disorders.
Type:
Grant
Filed:
February 6, 2008
Date of Patent:
November 17, 2009
Assignee:
Aventis Pharmaceuticals Inc
Inventors:
Gary Emmons, Sathapana Kongsamut, Craig N. Karson, Corrine M. Legoff
Abstract: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.
Type:
Grant
Filed:
May 19, 2005
Date of Patent:
November 17, 2009
Assignee:
Cognition Pharmaceuticals LLC
Inventors:
Mel H. Epstein, Kjesten A. Wiig, Randall L. Carpenter
Abstract: 2-Nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the 2-nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, also are disclosed.
Type:
Grant
Filed:
August 23, 2007
Date of Patent:
November 17, 2009
Assignee:
Evanston Northwestern Healthcare
Inventors:
Maria V. Papadopoulou, William D. Bloomer